## 3 Experimental Section  
### Synthesis of 1-(2-[N-(4-methoxybenzylidene)-hydrazino]-4-methylthiazol-5-yl]-ethanone  
6:  
Compound 6 was prepared as described in the literature method: m.p. 214-216 \({}^{\circ}\)C (Lit. m.p. 214-215 \({}^{\circ}\)C) [44]. \begin{table}
\begin{tabular}{r r r r r} \hline \multirow{2}{*}{**Compound No.**} & \multicolumn{4}{c}{**SC\({}_{50}\) Values (\(\mu\)M)**} \\ \cline{2-5}  & **HepG-2** & **HCT-116** & **MDA-MB-231** \\ \hline
**6** & 734.13 \(\pm\) 59.35 & 4.01 & 3.56 & 3.34 \\
**7** & 175.92 \(\pm\) 18.24 & 5.74 & 6.01 & 2.75 \\
**10b** & 181.89 \(\pm\) 15.07 & 4.47 & 4.04 & 3.10 \\
**10c** & 197.26 \(\pm\) 13.48 & 9.42 & 7.78 & 4.41 \\
**10d** & 109.74 \(\pm\) 5.92 & 2.21 & 2.07 & 1.29 \\
**10e** & 203.71 \(\pm\) 11.83 & 5.24 & 5.94 & 3.53 \\
**13a** & 214.65 \(\pm\) 14.21 & 3.75 & 4.15 & 2.20 \\
**13c** & 251.32 \(\pm\) 30.94 & 4.26 & 4.17 & 2.39 \\
**13d** & 229.14 \(\pm\) 17.29 & 4.66 & 5.07 & 2.68 \\
**13e** & 278.02 \(\pm\) 28.64 & 2.40 & 2.53 & 1.30 \\
**16** & 211.96 \(\pm\) 16.28 & 2.30 & 2.50 & 1.32 \\
**20** & 189.43 \(\pm\) 11.91 & 2.32 & 3.09 & 1.42 \\
**Cisplatin** & 58.75 \(\pm\) 3.87 & 6.81 & 4.83 & 4.97 \\ \hline \end{tabular} \({}^{*}\) The CC\({}_{50}\) values data that were measured as cytotoxic effects against normal human lung fibroblast (MRC-5) cell line (mean \(\pm\) standard error).  
\end{table} 
Table 4: The efficiency and selectivity indices of the investigated derivatives. \begin{table}
\begin{tabular}{r r r r} \hline \multirow{2}{*}{**Compound No.**} & \multicolumn{3}{c}{**IC\({}_{50}\) Values \({}^{*}\) (\(\mu\)M)**} \\ \cline{2-4}  & **HepG-2** & **HCT-116** & **MDA-MB-231** \\ \hline
**6** & 183.2 \(\pm\) 10.46 & 206.34 \(\pm\) 9.28 & 219.71 \(\pm\) 8.57 \\
**7** & 30.67 \(\pm\) 1.35 & 29.26 \(\pm\) 1.12 & 64.08 \(\pm\) 3.84 \\
**10b** & 40.73 \(\pm\) 1.29 & 44.98 \(\pm\) 1.36 & 58.63 \(\pm\) 4.71 \\
**10c** & 20.95 \(\pm\) 0.89 & 25.37 \(\pm\) 0.91 & 44.69 \(\pm\) 2.35 \\
**10d** & 49.57 \(\pm\) 1.37 & 53.02 \(\pm\) 1.26 & 85.4 \(\pm\) 2.19 \\
**10e** & 38.84 \(\pm\) 1.08 & 34.28 \(\pm\) 0.92 & 57.78 \(\pm\) 1.36 \\
**13a** & 57.26 \(\pm\) 1.44 & 51.78 \(\pm\) 1.39 & 97.42 \(\pm\) 3.95 \\
**13c** & 59.01 \(\pm\) 1.35 & 60.29 \(\pm\) 1.57 & 105.21 \(\pm\) 5.13 \\
**13d** & 49.15 \(\pm\) 1.23 & 45.23 \(\pm\) 1.19 & 85.64 \(\pm\) 4.12 \\
**13e** & 115.79 \(\pm\) 4.87 & 109.71 \(\pm\) 3.45 & 214.57 \(\pm\) 8.31 \\
**16** & 92.21 \(\pm\) 2.85 & 84.89 \(\pm\) 3.17 & 160.96 \(\pm\) 6.42 \\
**20** & 81.68 \(\pm\) 1.74 & 61.39 \(\pm\) 2.25 & 133.45 \(\pm\) 7.91 \\
**Cisplatin** & 8.63 \(\pm\) 0.51 & 12.16 \(\pm\) 0.68 & 11.83 \(\pm\) 0.79 \\ \hline \end{tabular} \({}^{*}\) The results are expressed as mean \(\pm\) standard error.  
\end{table} 
Table 3: The inhibitory activities of the examined compounds against different carcinoma cell lines (as IC\({}_{50}\) values). **Synthesis of hydrazinecarbontioamide derivative 7:**  
A catalytic amounts of HCl (two drops, 37%) was added to a mixture of acetylthiazole derivative **6** (2.89 g, 10 mmol), thiosemicbarazide **2** (0.91 g, 10 mmol) in EtOH (20 mL). The mixture was refluxed for 2 h (followed with TLC). The formed product was isolated by filtration and recrystallized from dioxane to give pure product thiosemicbarazone product **7** as white microcrystals, 78% yield; m.p. 210-212 \({}^{\circ}\)C; \(\delta_{\rm H}\): 1.81 (s, 3H, CH\({}_{3}\)), 2.50 (s, 3H, CH\({}_{3}\)), 3.80 (s, 3H, OCH\({}_{3}\)), 7.05 (d, 2H, \(J\) = 12 Hz, Ar-H), 7.75 (s, 2H, NH\({}_{2}\)), 7.83 (d, 2H, \(J\) = 12 Hz, Ar-H), 7.98 (s, 1H, N=CH), 11.30 (br s, 1H, NH), 11.95 (br s, 1H, NH) ppm; IR (KBr): \(v\) 3402, 3271, 3201, (NH\({}_{2}\) and 2 NH), 3055 2954 (C-H), 1604, 11438, 1273, 1063, 1030 cm\({}^{-1}\); MS _m/z_ (%): 362 (M\({}^{+}\)), 281, 163, 106, 91 (100), 78, 63. Anal. Calcd for C\({}_{15}\)H\({}_{18}\)N\({}_{6}\)OS\({}_{2}\) (362.47): C, 49.70; H, 5.01; N, 23.19. Found: C, 49.54; H, 5.00; N, 23.03%.